Netflix CEO Ted Sarandos yuks it up with Larry David and Jerry Seinfeld at a premiere earlier this year (Charley Gallay/Getty Images for Netflix)

Netflix’s record earnings help its stock keep rolling

A crackdown on password sharing, along with price hikes, keep boosting the bottom line. Shares are up after hours.

Matt Phillips

10/17/24 3:26PM

Streaming giant Netflix posted its biggest quarterly profit ever, up 41% in Q3 compared to last year, pushing the company’s shares up nearly 5% after hours. Earnings per share and revenue both beat Wall Street expectations.

The company’s stock hit a new all-time closing high of $722.79 on Wednesday, the result of a more than 40% romp in its price so far this year. That’s far outpaced the performance of comparable streaming and entertainment companies such as Disney, up about 7% in 2024, and Warner Brothers, which has been bludgeoned in the markets this year, losing more than 30%.

The excitement over Netflix has been justified, in part, by earnings reports like the one the Los Gatos, California, company just released, showing that it’s been able to sustainably boost profits to never-before-seen levels in recent quarters.

What’s driving the profits? At least in part, it’s been drawing on a price hike of its ad-free subscription tiers and cracking down on password sharing.

Nate Becker18h

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration.

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services' General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice "for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions."

Hims launched the product last week, a seeming copy of a recently released and patented drug, and immediately drew fire from Novo Nordisk and regulators.

Hims & Hers Comms on X

Hims launched the product last week, a seeming copy of a recently released and patented drug, and immediately drew fire from Novo Nordisk and regulators.

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

J. Edward Moreno2/6/26

$1.3M

Max Knoblauch2/6/26

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Texas Governor Abbott And Google Make Economic Development Announcement In Midlothian

Alphabet could buy some pretty huge businesses with the amount of money it plans to spend this year

AI outlays have gone full nut-nut. Even Google, one of the most capital-efficient businesses of all time in its heyday, is spending like there’s no tomorrow.

Tom Jones2/6/26

CFO Mandy Fields sees e.l.f. Beauty in growth mode, as company beats on sales and earnings

The new owner of rhode beat estimates for its fiscal third quarter and boosted its guidance for the full year, even as headwinds in the UK and Germany continued.

Claire Yubin Oh2/4/26